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Introduction: Ritonavir is a potential therapeutic agent in lung
cancer, but its targets in lung adenocarcinoma are unknown, as are
candidate biomarkers for its activity.
Methods: RNAi was used to identify genes whose expression
affects ritonavir sensitivity. Synergy between ritonavir, gemcitabine,
and cisplatin was tested by isobologram analysis.
Results: Ritonavir inhibits growth of K-ras mutant lung adenocar-
cinoma lines A549, H522, H23, and K-ras wild-type line H838.
Ritonavir causes G0/G1 arrest and apoptosis. Associated with
G0/G1 arrest, ritonavir down-regulates cyclin-dependent kinases,
cyclin D1, and retinoblastoma protein phosphorylation. Associated
with induction of apoptosis, ritonavir reduces survivin messenger
RNA and protein levels more than twofold. Ritonavir inhibits
phosphorylation of c-Src and signal transducer and activator of
transcription protein 3, which are important events for survivin gene
expression and cell growth, and induces cleavage of PARP1. Al-
though knock down of survivin, c-Src, or signal transducer and
activator of transcription protein 3 inhibits cell growth, only survivin
knock down enhances ritonavir inhibition of growth and survivin
overexpression promotes ritonavir resistance. Ritonavir was tested
in combination with gemcitabine or cisplatin, exhibiting synergistic
and additive effects, respectively. The combination of ritonavir/
gemcitabine/cisplatin is synergistic in the A549 line and additive in
the H522 line, at clinically feasible ritonavir concentrations (10
M).
Conclusions: Ritonavir is of interest for lung adenocarcinoma
therapeutics, and survivin is an important target and potential bio-
marker for its sensitivity. Ritonavir cooperation with gemcitabine/
cisplatin might be explained by involvement of PARP1 in repair of
cisplatin-mediated DNA damage and survivin in repair of gemcit-
abine-mediated double-stranded DNA breaks.
Key Words: Non-small cell lung cancer, Ritonavir, Survivin,
Chemotherapy.
(J Thorac Oncol. 2011;6: 661–670)
A potentially successful approach for cancer drug devel-opment consists of repurposing existing drugs, with
known tolerability, toxicity, and pharmacology.1 Ritonavir,
originally developed as a human immunodeficiency virus
drug, exhibits anticancer activity against epithelial malignan-
cies including prostate cancer, breast cancer, and ovarian
cancer,2–4 as well as Kaposi sarcoma5 and glioma,6 but its
potential inhibitory activity against lung adenocarcinoma is
unknown as are its mechanisms of action. The objective of
these studies was to determine whether ritonavir exhibits
effects on lung adenocarcinoma growth and survival and,
if so, which cancer-associated signaling pathways may be
affected in this malignancy. Identification of signaling
pathways affected by ritonavir in lung adenocarcinoma
could assist the design of clinical trials for recurrent/
metastatic disease, where there is an unmet need for new
therapeutic options.
One target of particular importance in lung cancer is the
antiapoptotic protein survivin.7 Survivin regulates multiple
cancer-relevant pathways and most notably inhibits apoptosis
as an inhibitor of apoptosis (IAP) family member, while
promoting cell cycle progression through the G1/S and G2/M
checkpoints.8–11 Because of its nodal role in cancer networks,
its short half-life,12 and its exclusive expression in tumor
tissues,13,14 survivin is a particularly attractive target in can-
cer therapy.15 Various approaches to down-regulate survi-
vin expression, including antisense oligonucleotides,16 ri-
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bozymes,17 siRNA,18,19 and dominant-negative protein,20
have been used successfully in preclinical setting in non-
small cell lung cancer (NSCLC) and other types of cancer.
Furthermore, a survivin antisense approach, alone or in com-
bination with chemotherapy, is being tested in clinical tri-
als.21,22 Survivin is highly expressed in NSCLC,7,13,23 and the
level of its gene expression may be prognostic of 5-year
survival,24 although correlation between survivin expression
and outcomes remains to be determined conclusively.25 Sur-
vivin may also play a role in the development of chemother-
apy resistance in NSCLC,26–28 and its down-regulation may
sensitize lung cancer to chemotherapy.29
Ritonavir is known to reduce the levels of survivin in
T-cell leukemia,30 but it is unknown whether ritonavir affects
the level or function of survivin in lung adenocarcinoma.
Because of the critical importance of survivin in NSCLC
biology and its outcomes, it was determined whether ritonavir
inhibits survivin also in NSCLC, specifically in lung adeno-
carcinoma cell lines. Survivin transcription is regulated by
c-Src and signal transducer and activator of transcription
protein (STAT)3, both known to be important for NSCLC
growth.31–34 Thus, the effects of ritonavir on these potential
targets were also studied. Finally, combinations of ritonavir
and chemotherapy that is not expected to interact pharmaco-
kinetically were tested for efficacy. Specifically, ritonavir was
combined with gemcitabine and cisplatin, because both drugs
have already been used in combination with ritonavir and
other human immunodeficiency virus protease inhibitors in
case reports and clinical trials.35–37
MATERIALS AND METHODS
Antisera
Antibodies raised against human phospho-retinoblas-
toma protein (Rb) (no. 9308), phospho-c-Src (no. 2101S),
STAT3 (clone 124H6; no. 9139), phospho-STAT3 (clone
3E2; no. 9138S), and PARP1 (no. 9542) were purchased from
Cell Signaling Technology (Beverly, MA). Antibodies raised
against p53 (clone DO1; no. sc-126), cyclin-dependent kinase
(CDK)2 (no. sc-163), CDK4 (no. sc-260), CDK6 (no. sc-
177), cyclin D1 (sc-718), and cyclin A (clone C-19; no.
sc-596) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibody c-Src (clone GD11; no. 05-184)
was purchased from Millipore (Billerica, MA). Antibodies
p27 (no. 610242), Rb (no. 554136), and phospho-Rb were
purchased from BD Biosciences (San Jose, CA). Antibody
survivin (no. AF886) was purchased from R&D Systems
(Minneapolis, MN). Antibody glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (clone 6C5; 10R-G109A) was pur-
chased from Fitzgerald Industries International (Concord, MA).
Cell Lines and Drugs
The lung adenocarcinoma lines A549, H522, and H23
were obtained from the American Type Culture Collection
(Manassas, VA). The lung adenocarcinoma line H838 was a
kind gift from Dr. Manish Patel (University of Minnesota).
Purified ritonavir, gemcitabine, and cisplatin were purchased
from Sequoia Research Products (Pangbourne, UK).
siRNA
siRNA duplex SMARTpool upgrades of c-Src (no.
M-003175-03), STAT3 (no. M-003544-02), survivin (no.
M-003459-02), and siControl (no. D-001210-01) were pur-
chased from Dharmacon Research, Inc. (Lafayette, CO). The
sequences for siRNA duplexes used in these studies are given
in Table S1 (http://links.lww.com/JTO/A62).
Western Blotting
Cell lysates were prepared by standard methodology.
Samples containing the same amount of protein were sepa-
rated on a 4 to 20% gradient SDS gel, blotted on a nitrocel-
lulose membrane, and probed with specific antibodies. Den-
sitometric analysis of the bands was performed using the
software Alpha Imager (Alpha Innotech; San Leandro, CA),
and the relative amount of protein was normalized to the
corresponding signal for GAPDH.
3, [4,5-Dimethylthiazol-2-yl]-2,5-
Diphenyltetrazolium Bromide Assay
The cells were cultured in 96-well plates for 48 hours in
the presence of increasing concentration of ritonavir (ranging
from 5 to 60 M) or dimethyl sulfoxide (DMSO). Cell
growth was determined by measuring the mitochondrial re-
duction of the tetrazolium salt, 3, [4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) (Sigma; St Louis,
MO). Each concentration of ritonavir was tested in octupli-
cate, and each MTT assay was repeated three times.
Measurement of Clonogenic Efficiency
Clonogenic efficiency of lung adenocarcinoma lines
was measured by exposing cell monolayers (20% confluent)
to varying concentrations of ritonavir (ranging from 10 to 100
M) or DMSO for 24 hours. Each ritonavir concentration
was tested in triplicate. At the end of the 24-hour treatment,
cell monolayers were treated with trypsin and replated (500
cells/100-mm plate) in the absence of ritonavir in complete
medium (CM) consisting of RPMI 1640 (American Type
Culture Collection; Manassas, VA) supplemented with 10%
fetal calf serum (Hyclone/Thermo Fisher Scientific; Logan,
UT). The medium was changed every 3 days for 21 days. At
the end of the 21-day incubation period, the colonies were
fixed, stained with Wright-Giemsa stain (Thermo Fisher Sci-
entific; Waltham, MA), and counted.
Cell Cycle Analysis
Lung adenocarcinoma cell lines 30 to 50% confluent
were treated with trypsin, washed, and resuspended in CM.
Cells were plated at a density of 5  105 cells/100-mm plate
and grown for 24 and 48 hours in CM in the presence of
ritonavir (half maximal inhibitory concentration [IC50]) or
DMSO. Profiling of propidium iodide (PI) incorporation was
performed by FACScan analysis (Becton Dickinson; San
Jose, CA). Adherent and nonadherent cells were included in
the profile. Cell cycle distribution was determined using
ModFit software (Becton Dickinson; San Jose, CA).
Measurement of Apoptosis
Apoptotic cells were detected using an Annexin-V-
FITC/PI apoptosis detection kit (Oncogene; Boston, MA).
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Cells were plated at a density of 5  105 cells/100-mm plate
and grown for 48 hours in CM in presence of ritonavir (IC50)
or DMSO. After 48 hours, cells were harvested and stained
with PI and Annexin-V-FITC. Cells were then acquired by
FACScan (1 104 cells/assay) and analyzed using CellQuest
software (Becton Dickinson; San Jose, CA). Each assay was
performed in duplicate.
Real-Time Polymerase Chain Reaction
RNA was isolated from A549 and H522 cell lines
treated for 48 hours with ritonavir (40 M) or DMSO by
RNeasy mini kit (QIAGEN; Valencia, CA), following man-
ufacturer’s instructions. First-strand complementary DNA
(cDNA) was synthesized with high-capacity cDNA archive
kit (Applied Biosystems; Foster City, CA). The polymerase
chain reaction consisted of 40 cycles (2 minutes at 50°C, 10
minutes at 95°C, 15 seconds at 95°C, and 1 minute at 60°C).
siRNA Transfection and Cell Survival Assay
Cells were plated in six-well poly-D-lysine-coated tis-
sue culture plates (Becton Dickinson; Bedford, MA) at 2.5 
104 cells/well, grown for 24 hours, and then transfected with
50 pmol/well of siRNA duplexes for c-Src, STAT3, survivin,
or control siRNA using oligofectamine (Invitrogen; Carlsbad,
CA) and OPTI-MEM (Invitrogen; Carlsbad, CA). The effi-
cacy of gene silencing was evaluated by examining the
protein product with Western blotting 72 hours after trans-
fection. Each assay was performed in triplicate. Twenty-four
hours after the siRNA transfection, the cells were exposed for
48 hours to ritonavir (ranging from 0 to 60 M), and cell
viability was measured by an MTT assay.
Generation of Survivin Expression MIEG3
Vectors
Human survivin cDNA was cloned upstream of the
internal ribosomal entry site for enhanced green fluorescence
protein (EGFP). The survivin sense orientation expression
plasmid (S-IRES-EGFP-MIEG3) was constructed using an
EcoRI adaptor as described.10 Empty MIEG3 plasmid was
used as control vector. Flow cytometry was used to sort A549
or H522 cells transiently transfected with the S-IRES-EGFP-
MIEG3.
Effects of Drug Combination on Cell Growth
Cells were exposed to ritonavir and/or gemcitabine at a
fixed constant ratio corresponding to the ratio of the IC50
values for each single drug. The CalcuSyn software (Biosoft;
Cambridge, UK)—which uses the median-effect analysis
method of Chou and Talalay—was used to determine the
possible synergic effect of the drugs. According to this
method, a combination index (CI) can be calculated from
dose-response curves obtained using the drugs as single agent
or in combination. CI value less than 1.0 indicates synergy,
CI  1.0 indicates that the drugs act in an additive fashion,
and CI more than 1.0 indicates antagonism.
Statistical Analysis
Statistical analysis was conducted using two-tailed Stu-
dent’s t test (Excel, Microsoft). A difference was considered
significant if p value was less than 0.05.
RESULTS
Ritonavir Inhibits Growth and Colony
Formation of Lung Adenocarcinoma Lines
The effect of ritonavir on the growth of the A549 and
H522 lines was assayed by MTT assay and compared with
vehicle (DMSO). Ritonavir inhibits the growth of the lung
adenocarcinoma lines A549 and H522, exhibiting IC50 values
of 35 and 42 M, respectively (Figure 1A). Ritonavir also
inhibits the growth of the lung adenocarcinoma lines H23 and
H838, exhibiting IC50 values of 44 and 35 M, respectively,
confirming that ritonavir is active across a range of lung
adenocarcinoma lines (results for H23 not shown; results for
FIGURE 1. Panel A, Ritonavir inhibits growth of the lung
adenocarcinoma lines A549 and H522. Ritonavir inhibited
the growth of both lines, exhibiting an half maximal inhibi-
tory concentration (IC50) of 35 M for A549 (open circles)
and 42 M for H522 (open squares). Results are representa-
tive of three consistent experiments. Panel B, Ritonavir reduces
the clonogenic efficiency of the lung adenocarcinoma lines
A549 and H522. Ritonavir was efficient in reducing the clono-
genic efficiency in both the A549 (open circles) and H522
(open squares) lines, exhibiting an IC50 of 30 and 40 M, re-
spectively. Panel C, Ritonavir induces apoptosis of the lung ade-
nocarcinoma lines A549 and H522. Ritonavir significantly in-
creased early- and late-apoptotic events in both lines. The
results are representative of two consistent experiments.
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H838 shown in Figure S1; http://links.lww.com/JTO/A61).
Ritonavir was also effective at inhibiting adhesion-dependent
colony formation of the A549 and H522 lines, exhibiting IC50
values of 30 and 40 M, respectively (Figure 1B).
Ritonavir Induces Apoptosis of Lung
Adenocarcinoma Lines
To determine whether ritonavir induces apoptosis, the
adenocarcinoma lines A549 and H522 were exposed to
ritonavir at the IC50 for 48 hours, stained with PI/Annexin-
V-FITC and analyzed by flow cytometry. Ritonavir treatment
increased the percentage of early-apoptotic cells 10-fold from
1.6 to 16%, for the A549 line, and threefold, from 3.2 to 10%,
for the H522 line (Figure 1C). The percentage of late-
apoptotic cells increased 10-fold, from 0.6 to 5.9% for the
A549 line, and twofold from 0.6 to 1.1% for the H522 line.
Ritonavir Induces a G0/G1 Cell Cycle Arrest
To determine whether ritonavir inhibits cell cycle progres-
sion of lung adenocarcinoma cells, the A549 and H522 lines
were grown in the presence of ritonavir at either its IC50 (40
M) or half the IC50 (20 M) or in the presence of vehicle
(DMSO) for 24 and 48 hours. The cell cycle distribution was
determined by flow cytometry. For both lines, incubation with
ritonavir for 48 hours resulted in a dose-dependent G0/G1 cell
cycle block, as demonstrated by increase of the G0/G1 population
and by a corresponding reduction of the S and G2/M populations
(Figure 2A, Table S2 [http://links.lww.com/JTO/A62]). Similar
results were obtained after 24 hours incubation with ritonavir
(results not shown).
Ritonavir Down-Regulates CDK2, CDK4, CDK6,
and Cyclin D1 Levels and Inhibits pRb, While
Up-Regulating p27Kip1and Wild-Type p53
Because ritonavir induces a G0/G1 block in lung adeno-
carcinoma lines (Figure 2A), it was investigated whether ritona-
vir affects the levels of proteins known to regulate the G1/S
checkpoint. Both the A549 and H522 lines exhibit reduction of
G1/S checkpoint regulators CDK2, CDK4, CDK6, and cyclin
D1, after 48 hours of treatment at the ritonavir IC50 (Figure
2B; Table S3 [http://links.lww.com/JTO/A62]). Correlating
with reduction of CDKs and cyclin D1, phospho-Rb levels
were reduced by more than 80% (Figure 2B; Table S3
[http://links.lww.com/JTO/A62]). Cyclin A, involved in S
phase progression, was also decreased by ritonavir (Figure 2B;
Table S3 [http://links.lww.com/JTO/A62]). Furthermore,
p27Kip1, an important inhibitor of cyclin E/CDK2 complexes,
was increased in both lines. The A549 line is p53 wild type,
whereas the H522 line is p53 mutant (codon 191), and the
effects of ritonavir differed, with p53 increasing in the wild-type
line and decreasing in the mutant line (Figure 2B and Table S3
[http://links.lww.com/JTO/A62]).
Effects of Ritonavir on Survivin, c-Src, STAT3,
and Cleaved PARP1 Levels in Lung
Adenocarcinoma Lines
The potential roles of survivin, its up-stream regulatory
proteins c-Src and STAT3 and their phosphorylated forms,
and its down-stream signaling molecule PARP were studied
in the A549 and H522 lines. Ritonavir treatment significantly
reduced survivin expression in both cell lines (Figure 3A;
Table S4a [http://links.lww.com/JTO/A62]). In both lines,
FIGURE 2. Panel A, Ritonavir causes G0/G1 cell cycle arrest in the A549 and H522 lung adenocarcinoma lines. Ritonavir was
able to induce a G0/G1 block as demonstrated by increase of the G0/G1 population and by a corresponding reduction of the
S and G2/M populations. Cells grown with ritonavir or vehicle are indicated with () and (), respectively. For quantitation
of the flow cytometry analysis, see Table 2S [http://links.lww.com/JTO/A62]. Panel B, Ritonavir down-regulates the expression
of numerous cell cycle-associated proteins in the lung adenocarcinoma lines A549 and H522. CDK2, CDK4, CDK6, cyclin D1,
cyclin A, phospho-retinoblastoma protein (Rb), and Rb levels were reduced in both lines treated with ritonavir. Levels of p53
were reduced in the H522 line but increased in the A549 line. The levels of p27Kip1 were increased in both lines. For quantita-
tion of the Western blots, see Table S3 [http://links.lww.com/JTO/A62].
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ritonavir reduced fractional phosphorylation of c-Src by more
than half (Figure 3A; Table S4a [http://links.lww.com/JTO/
A62]). Total c-Src was also reduced in the H522 line but not
A549 (Figure 3A; Table S4a [http://links.lww.com/JTO/A62]).
Ritonavir treatment reduced the fractional phosphorylation of
STAT3 by 40% in both cell lines but did not affect STAT3
levels (Figure 3A; Table S4a [http://links.lww.com/JTO/A62]).
In both lines, ritonavir significantly increased the levels of
cleaved PARP1 (Figure 3A; Table S4a [http://links.lww.com/
JTO/A62]).
Effects of Ritonavir on Survivin mRNA Levels in
Lung Adenocarcinoma Lines
To determine whether reduction in survivin protein
levels by ritonavir corresponds to a down-regulation of its
message, survivin mRNA levels were measured by real-time
polymerase chain reaction. Survivin mRNA was reduced by
70 to 80% in ritonavir-treated lung adenocarcinoma lines
(Figure 3B). These results indicate that ritonavir-mediated
reduction of survivin is mediated largely through reduction of
survivin mRNA.
RNAi Profiling of Survivin or Its Regulators
c-Src and STAT3 Reveals that Survivin is the
Most Important Ritonavir Target
Recently, RNAi silencing has been used to identify
genes whose expression affects drug responses in cancer.38 In
this study, the regulatory pathway for survivin expression,
which is mediated by c-Src and STAT3, was profiled by
RNAi with the purpose of testing the relative importance of
the members of this pathway as ritonavir targets. To verify
the effectiveness of the RNAi approaches, the protein levels
of survivin, c-Src, and STAT3 were determined. Knock down
of c-Src, STAT3, and survivin reduced their corresponding
proteins by 50, 70, and 50%, respectively (Figure 4A, Table
S4b [http://links.lww.com/JTO/A62]). Knock down of c-Src
significantly reduced survivin and STAT3 levels in both
lines, indicating that there is a direct relationship between
c-Src levels and its downstream signaling proteins (Figure
4A, Table S4b [http://links.lww.com/JTO/A62]). Knock
down of STAT3 reduced survivin in the H522 line only
(Figure 4A, Table S4b [http://links.lww.com/JTO/A62]).
These results indicate that survivin levels are determined, in
part, by c-Src and STAT3 levels, confirming a model of a
signaling hierarchy between these regulatory proteins in
NSCLC. Inhibitory effects of survivin, c-Src, and STAT3
knock down on the ritonavir-sensitive lung adenocarcinoma
lines were verified by MTT assay. siRNA targeting c-Src,
STAT3, or survivin significantly inhibits the growth of both
the A549 and H522 lines at 48 hours (Figure 4B). After
establishing the effectiveness of the RNAi silencing of c-Src,
STAT3, and survivin, this approach was used to determine
the relative importance of the survivin pathway members as
ritonavir targets. Only survivin knock down shifted the MTT
dose-response curve significantly to the left for the A549 and
H522 lines, indicating the importance of survivin levels for
ritonavir sensitivity (Figure 4C). In contrast, despite the
hierarchy placing c-Src and STAT3 up-stream of survivin,
c-Src, STAT3, and nontarget RNAi failed to affect the ritona-
vir IC50 for either line. After survivin RNAi treatment, the
ritonavir IC50 decreased to 25 M for both lines (Figure 4C).
Testing ritonavir at its IC50 in combination with survivin
siRNA confirmed that reduction of survivin sensitizes lung
cancer lines to ritonavir (Figure 4D).
Overexpression of Survivin Induces Resistance
to Ritonavir in Lung Adenocarcinoma Lines
Because survivin knock down sensitizes lung adeno-
carcinoma lines to ritonavir, it was determined whether sur-
vivin overexpression leads to ritonavir resistance. Survivin
expression was increased threefold in both lines by the
FIGURE 3. Panel A, Ritonavir down-regulates the expression of phospho-c-Src, Src, phospho signal transducer and activator
of transcription protein (STAT)3, and survivin and increases cleaved PARP in the lung adenocarcinoma lines A549 and H522.
Both in the A549 and H522 line, ritonavir reduced phospho-c-Src, phospho-STAT3, and survivin levels, whereas it increased
the cleaved PARP levels; it did not affect total STAT3 levels, and it down-regulated total c-Src only in the H522 line. Cells
growth with ritonavir or vehicle are indicated with () and (), respectively. For quantitation of the Western blots, see Table
S4a [http://links.lww.com/JTO/A62]. Panel B, Ritonavir down-regulates survivin mRNA in the lung adenocarcinoma lines
A549 and H522. After 48 hours of treatment, ritonavir drastically reduced the levels of survivin messenger RNA (mRNA)
in both lines.
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S-IRES-EGFP-MIEG3 transfection (Figure 5A). Transfection
with the survivin expression plasmid resulted in significant
increases of the ritonavir IC50 for both lines (by 10–20 M)
(Figure 5B). Therefore, survivin overexpression causes resis-
tance to ritonavir, whereas survivin knock down causes
sensitivity, identifying survivin as a critical target for this
drug.
Ritonavir Exhibits Enhanced Anticancer Activity
When Combined with Gemcitabine and/or
Cisplatin
After identifying ritonavir inhibitory activity in lung
adenocarcinoma lines and survivin as its major target, it was
important to learn effective ways of combining ritonavir with
other chemotherapy agents. This goal can be accomplished
by identifying chemotherapy drugs that do not interact phar-
macokinetically with ritonavir, thereby avoiding drug inter-
actions that could cause unpredictable toxicity. Ritonavir is
known to interact with drugs metabolized by CYP3A4, by
either decreasing or increasing their metabolism.39 For in-
stance, as a CYP3A4 inhibitor, ritonavir is known to boost the
levels of chemotherapy drugs, such as taxanes, vinca alka-
loids, and etoposide, making toxicity difficult to predict.40,41
In contrast, the widely used lung cancer drug gemcitabine is
not known to interact with ritonavir, and as such, it represents
a promising candidate for combined therapy. When gemcit-
abine was combined with ritonavir at the respective IC50 for
each drug, reduction of survivin was still observed, indicating
that gemcitabine does not interfere with ritonavir-mediated
reduction of survivin (Figure 6A, Table S5 [http://links.lww.
com/JTO/A62]). Furthermore, in the A549, gemcitabine
alone significantly reduced survivin levels, and such reduc-
tion was enhanced by the combination ritonavir/gemcitabine.
When tested for synergy by Chou-Talalay42 isobologram
analysis, the combination ritonavir/gemcitabine exhibited
strong synergy (Figure 6B) with combination index (CI)
values for the A549 and H522 lines of 0.57  0.33 and
0.16  0.09, respectively. Ritonavir exhibits an IC50 of 15 to
20 M in combination with gemcitabine concentrations of 15
FIGURE 4. Panel A, c-Src, STAT3, and sur-
vivin siRNA reduce the levels of their target
proteins. The () column indicates nontar-
get siRNA, whereas the () column indi-
cates specific siRNA as labeled. The siRNA to
c-Src, STAT3, and survivin reduced the level
of the corresponding protein in all three
lines. For quantitation of the Western blots,
see Table S4b [http://links.lww.com/JTO/
A62]. Panel B, siRNA targeting c-Src, STAT3,
and survivin reduces growth of the lung ad-
enocarcinoma lines A549 and H522. Cells
treated with siRNA targeting c-Src, STAT3,
and survivin exhibited reduced growth,
when compared with cells treated with non-
targeting siRNA. p value of 0.05 is indi-
cated with an asterisk. Panel C, siRNA tar-
geting c-Src or STAT3 does not reduce
ritonavir half maximal inhibitory concentra-
tion (IC50) for the lung adenocarcinoma
lines A549 and H522. A549 and H522 cells
transfected with siRNA targeting c-Src,
STAT3, survivin, or nontargeting siRNA were
grown in the presence of increasing con-
centrations of ritonavir. Silencing of survivin
mRNA expression increased the cell sensitiv-
ity to ritonavir, reducing its IC50 to 25 M
for the A459 line and 27 M for the H522
line. Panel D, siRNA targeting survivin in-
creases the sensitivity to ritonavir of the
lung adenocarcinoma lines A549 and H522.
A549 and H522 cells transfected with siRNA
targeting survivin were treated with ritona-
vir at the appropriate IC50. Survivin siRNA
and ritonavir acted together to reduce cell
growth in both lines. p value of 0.05 is
indicated with an asterisk.
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to 60 nM, which are well below Cmax concentrations attained
clinically with gemcitabine monotherapy.43,44 Also cisplatin,
which is commonly used in lung cancer chemotherapy, is not
known to interact with ritonavir. The ritonavir/cisplatin com-
bination was less active in inhibiting the growth of lung
adenocarcinoma lines than the ritonavir/gemcitabine combi-
nation, exhibiting CI values of 1  0.55 and 1.1  1.16 for
the A549 and H522 lines, respectively (Figure 6B). These CI
values indicate that cisplatin and ritonavir are additive rather
than synergistic for the A549 and H522 lines.42 Similarly to
what we observed for the combination ritonavir/gemcitabine,
ritonavir IC50 was reduced to 20 M in combination with
cisplatin at 4.5 M.
As the combination gemcitabine/cisplatin is a standard
regimen for the treatment of lung adenocarcinoma,45 we also
tested the effect of ritonavir in combination with gemcitabine/
cisplatin in the A459 and H522 lines. The ritonavir/gemcit-
abine/cisplatin combination acted synergistically in the A549
line (CI  0.6  0.2) and was slightly superior to the
combination gemcitabine/cisplatin (Figure 6C). On the other
hand, in the H522 line, the combination ritonavir/gemcit-
abine/cisplatin acted additively (CI  0.9  0.2), but it was
inferior to the gemcitabine/cisplatin combination (Figure 6C).
Importantly, in both cell lines, ritonavir IC50 was less than 10
M in combination with concentrations of gemcitabine and
cisplatin well below their IC50.
DISCUSSION
Survival of recurrent/metastatic NSCLC with palliative
chemotherapy fails to exceed 1 year, and there is an unmet
need for new drugs and drug combinations that work
through novel mechanisms.46 In this study, we propose
ritonavir as a candidate drug for metastatic lung adenocar-
cinoma clinical trials, based on its inhibition of adenocar-
cinoma lines at concentrations in the 35 to 45 M range.
Such concentrations are clinically attainable, albeit with
significant gastrointestinal toxicity,47 with ritonavir mono-
therapy at 600 mg twice daily.48
Study of signaling pathways affected by ritonavir by
siRNA profiling revealed that survivin is an important target,
whereas c-Src and STAT3 seem to be of lesser importance.
Furthermore, forced overexpression of survivin confers rela-
tive resistance to ritonavir, confirming importance of survivin
as a ritonavir target. Ritonavir reduces survivin, in part, by
reducing its mRNA levels. Because survivin is regulated in
cancer primarily through its mRNA expression,49 these re-
sults suggest that ritonavir is likely attacking a basic mech-
anism of survivin transcriptional regulation.
Ritonavir inhibits lung adenocarcinoma growth and
anchorage-dependent clonogenicity, in part, by inducing
G0/G1 cell cycle arrest and, in part, by inducing apoptosis.
Survivin is implicated in regulation of the G1/S8,9,11 and
G2/M checkpoint, and therefore, its reduction by ritonavir is
expected to cause inhibition of the cell cycle. Ritonavir may
also inhibit the G1/S checkpoint through down-regulation of
CDKs, cyclin D1, and associated Rb phosphorylation, as well
as by induction of p27Kip and wild-type p53. Although
reduction of survivin by ritonavir is expected to promote
apoptosis in lung cancer presumably related to loss of the
antiapoptotic effect of survivin,50 the remaining mechanisms
by which ritonavir induces apoptosis remain to be deter-
mined. These mechanisms could include induction of DNA
damage, in part, through increased cleavage of PARP1.
Importantly, drug combination studies revealed that
ritonavir is active at lower concentrations when combined
with gemcitabine, cisplatin, and the gemcitabine/cisplatin
combination. In combination with gemcitabine or cisplatin,
ritonavir exhibits IC50 values in the range of 15 to 20 M.
With the gemcitabine/cisplatin combination, the ritonavir
IC50 is in the 8 M range, which should be attainable with
100 mg twice daily dosing.48 Although the gemcitabine/
cisplatin combination in advanced NSCLC resulted in the
longest median time to progression compared with three other
chemotherapy doublets, this was only 4.2 months.45 We
hypothesize, based on in vitro synergy, that addition of
low-dose ritonavir to the gemcitabine/cisplatin combination
may improve time to progression, with acceptable toxicity.
Furthermore, because ritonavir is not myelosuppressive and
potentially could be continued through the period of gemcit-
abine/cisplatin treatment, ritonavir could potentially inhibit
regrowth of lung adenocarcinoma between cycles of chemo-
therapy. Therefore, a phase I study of daily ritonavir in
FIGURE 5. Panel A, Overexpression of survivin in the lung
adenocarcinoma lines A549 and H522. Cells transiently
transfected with human survivin complementary DNA
(cDNA) had significantly higher levels of survivin, when com-
pared with cells transfected with the empty vector. Panel B,
Overexpression of survivin increases resistance of the lung ade-
nocarcinoma lines A549 and H522 to ritonavir. Overexpression
of survivin reduced the cell sensitivity to ritonavir, increasing its
half maximal inhibitory concentration (IC50) to 45 M for the
A549 line and 55 M for the H522 line.
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FIGURE 6. Panel A, Gemcitabine and ritonavir down-regulate the survivin levels of the lung adenocarcinoma lines A549 and
H522. Ritonavir was able to reduce the levels of survivin either when used alone or together with gemcitabine. For quantitation of
the Western blots, see Table S5 [http://links.lww.com/JTO/A62]. Panel B, Ritonavir and gemcitabine synergize in inhibiting the
growth of the lung adenocarcinoma lines A549 and H522. The combination gemcitabine and ritonavir had a synergic effect and
was significantly more effective in reducing growth compared with each drug alone. On the other hand, the combined effect of
ritonavir and cisplatin was additive for the A549 and H522 lines. Panel C, The combination ritonavir/gemcitabine/cisplatin is synergistic in
the A549 line and additive in the H522 line. The concentrations of ritonavir (R), gemcitabine (G), and cisplatin (C) are indicated on the x
axis. The combination ritonavir/gemcitabine/cisplatin acted synergistically in the A549 line and additively in the H522 line. The combina-
tion gemcitabine/cisplatin was superior to ritonavir/gemcitabine/cisplatin in the H522 line but not in the A549 line.
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combination with the established gemcitabine and cisplatin
schedule is an important next step. Although K-ras mutation
status did not affect sensitivity to ritonavir, for the H838
K-ras wild-type line, there was lack of synergy with gemcit-
abine and antagonism with cisplatin. These results suggest
that K-ras mutant lung adenocarcinoma is the best candidate
histology for future clinical trials.
Although the mechanisms behind cooperation between
ritonavir and gemcitabine and/or cisplatin are not known, it is
likely these mechanisms involve survivin effects on DNA
repair pathways. Gemcitabine is a DNA-strand terminator
that stalls replication forks, causes S-phase arrest,51 and
double-strand breaks (DSBs) while inhibiting homologous
recombination repair, which is required for repairing
DSB.52,53 Survivin has been reported to enhance DSB repair,
and we hypothesize that reduction of survivin by ritonavir
may increase sensitivity to gemcitabine through this mecha-
nism.54 Survivin reduction may also explain sensitivity of
lung adenocarcinoma to ritonavir in combination with cispla-
tin due to increased PARP1 cleavage.
PARP1 may be involved in repair of cisplatin-induced
DNA damage. PARP1 is known to recruit XRCC1 to sites of
DNA damage.55 XRCC1 is a scaffolding factor required for
base excision repair56 and recently, nucleotide excision repair
(NER).57 Of interest, interference with NER interferes with
repair of cisplatin-induced DNA damage.53 Although PARP1
has not been implicated as a key regulator of NER, it has been
recently been located at sites of cisplatin-induced DNA dam-
age, by two photoaffinity labeling studies.58,59 This finding
potentially implicates PARP1 in repair of cisplatin-mediated
DNA interstrand crosslinks by NER. In addition, PARP1
reduction has also recently been demonstrated to play a
critical role in chemosensitivity to the gemcitabine/cisplatin
combination in triple-negative breast cancer.60 Future studies
will determine the mechanisms by which ritonavir may en-
hance DNA damage by cisplatin and gemcitabine.
On the basis of the importance of survivin as a ritonavir
target in lung adenocarcinoma, we propose that survivin may
be a useful biomarker for ritonavir sensitivity. We hypothe-
size that among tumors expressing survivin, those exhibiting
lower survivin levels will be more likely to respond to
ritonavir. Our results from forced survivin overexpression are
artificial and may not reflect survivin levels in tumors occur-
ring in patients, and therefore, we would not recommend
excluding patients with high-survivin levels from clinical
trials of ritonavir. Only the analysis of data from such trials
would reveal whether there is a relationship between survivin
levels and ritonavir sensitivity.
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